Early Lung Cancer Detection Using the Self-Evaluation Scoring Questionnaire and Chest Digital Radiography: A 3-Year Follow-up Study in China

Abstract

The standard definition of high-risk individuals for lung cancer was not uniform and the value of chest digital radiography (DR) in lung cancer screening was still unproven. The aim of this study was to assess whether the original questionnaire named as "Self-evaluation Scoring Questionnaire for High-risk Individuals of Lung Cancer" combined with DR examinations could detect early stage of lung cancer effectively. The Self-evaluation Scoring Questionnaire for High-risk Individuals of Lung Cancer had been designed in previous studies. Subjects with scores over 116 points were regarded as high-risk individuals and underwent the current DR scans at least once a year from 2007 to 2009. Noncalcified nodules with a diameter over 30 mm, along with enlarged pulmonary hilus and atelectasis, were considered to be positive and subjected to further special examinations. Efficacy of the scoring questionnaire combined with DR scans was estimated by 3-year results. Among 1,537 subjects, 13, 11, and 7 were diagnosed with lung cancer in the first, second, J Digit Imaging (2013) 26:72-81 DOI 10.1007 and third year, respectively, indicating the detection rate of 2.02 % (31/1,537). In addition, 77.42 % (24/31) of the patients were in stage I and 51.61 % (16/31) were adenocarcinomas. For the 31 cases, 28 were defined as detected cancers, while the other three were interval ones, only accounting for 0.20 % (3/1,504) of individuals with negative judgments. The protocol of Self-evaluation Scoring Questionnaire for High-risk Individuals of Lung Cancer combined with DR scans is a cost-effective and safe approach to detect early stage of lung cancer.

Real-world hospital costs for nonchemotherapy drugs and nondrug care associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small-cell lung cancer in Chinese patients: a retrospective cohort study

“… 2 , 3 Similar to the tumor histology distribution of lung cancer in industrialized countries, >80% of diagnosed lung cancer in Chinese patients is non-small-cell lung cancer (NSCLC). 4 Because of the challenges associated with early detection, 5 NSCLC is often diagnosed at advanced stage 6 in Chinese patients, and chemotherapy is the main therapeutic option 7 that may extend survival and improve quality of life in patients with advanced NSCLC over best supportive care alone. 8 With substantially increased reimbursement coverage for hospital care in the People’s Republic of China, 9 health resource utilization associated with chemotherapy for advanced NSCLC has become an important consideration for both clinical and reimbursement decision-making.…”

Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study

“…Non-small cell lung cancer (NSCLC) accounts for over 80% of lung cancer cases in China [ 4 ]. Because of the challenges associated with tumor early detection [ 5 ], more than half of Chinese patients with lung cancer are diagnosed at an advanced stage [ 6 ], which is not curable and is associated with a 5-year survival rate of less than 10% [ 7 ]. Thus, chemotherapy is the main therapeutic option to extend survival and to improve the quality of life in Chinese patients with advanced lung cancer [ 8 ].…”